Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
DexCom, Inc. is a medical device company specializing in continuous glucose monitoring (CGM) systems for people with diabetes and related metabolic conditions. The company operates within the medical devices, digital health, and diabetes care industries, with a core focus on real-time glucose sensing technologies that reduce the need for fingerstick testing. DexCom’s products are primarily used by individuals with Type 1 diabetes and insulin-dependent Type 2 diabetes, as well as by healthcare providers who manage chronic glycemic conditions.
DexCom’s primary revenue drivers are its CGM systems, including sensors, transmitters, and receivers, supported by mobile software platforms that integrate with smartphones, insulin pumps, and digital health ecosystems. The company is widely recognized for its accuracy, ease of use, and interoperability with insulin delivery devices, which provides a strategic advantage in both clinical adoption and patient retention. Founded in 1999, DexCom initially focused on short-term glucose sensors for hospitals before transitioning to long-term wearable CGM systems, a shift that established the company as a leading independent CGM manufacturer globally.
Business Operations
DexCom generates revenue primarily through the sale of disposable sensors and reusable transmitters that are replaced on a recurring basis, creating a consumables-driven revenue model. Its operations are organized around the design, manufacturing, and commercialization of CGM platforms, with its flagship product lines including Dexcom G6 and Dexcom G7, which offer real-time glucose readings, predictive alerts, and data-sharing capabilities. Software applications and cloud-based data services support these devices but are not currently material standalone revenue contributors.
The company conducts operations across both domestic and international markets, with manufacturing and assembly supported by a mix of internal facilities and third-party contract manufacturers. DexCom maintains integration partnerships with insulin pump manufacturers and digital health platforms, enabling interoperability with automated insulin delivery systems. The company operates through wholly owned subsidiaries in key markets to manage regulatory approvals, reimbursement, and localized distribution.
Strategic Position & Investments
DexCom’s strategic direction centers on expanding CGM adoption beyond intensive insulin users to broader Type 2 diabetes populations and non-intensive insulin users, while also improving affordability and access through pharmacy channels. Growth initiatives include continued miniaturization of sensors, longer wear duration, and enhanced software analytics that support population health and remote patient monitoring. The company has consistently invested in research and development to maintain technological leadership and defend its competitive position against integrated device manufacturers.
Strategic investments have largely focused on internal product development rather than large-scale acquisitions, with selective acquisitions and technology licenses used to enhance sensor performance, manufacturing efficiency, and data capabilities. DexCom has also expanded collaborations with insulin pump manufacturers and digital health partners to embed its CGM technology within closed-loop and hybrid closed-loop insulin delivery systems, positioning the company at the center of emerging automated diabetes management ecosystems.
Geographic Footprint
DexCom is headquartered in North America, with its corporate headquarters located in San Diego, California. The company maintains a strong market presence in the United States, which represents its largest revenue base, supported by widespread insurance reimbursement and clinical adoption. Internationally, DexCom has established significant operations across Europe, Asia-Pacific, and select markets in Latin America through subsidiaries and distribution partners.
The company continues to expand its international footprint by securing regulatory approvals and reimbursement coverage in additional countries, particularly in Western Europe and developed Asia-Pacific markets. Manufacturing and research facilities are primarily located in the United States, with international offices supporting sales, regulatory affairs, and customer service, reinforcing DexCom’s global operational influence in diabetes technology.
Leadership & Governance
DexCom is led by an experienced executive team with deep expertise in medical devices, diabetes care, and regulated healthcare markets. The leadership emphasizes innovation, clinical evidence generation, and patient-centric product design, with a strategic vision focused on expanding access to CGM technology while maintaining high standards of accuracy, reliability, and regulatory compliance.
Key executives include:
- Kevin R. Sayer – Chairman, President, and Chief Executive Officer
- Jereme M. Sylvain – Chief Financial Officer
- Jake Leach – Executive Vice President and Chief Operating Officer
- Matt Dolan – Executive Vice President and Chief Commercial Officer
- Andy Balo – Executive Vice President and Chief Technology Officer